Share on StockTwits

Investment analysts at Jefferies Group reduced their price objective on shares of Durata Therapeutics (NASDAQ:DRTX) from $15.00 to $12.00 in a note issued to investors on Friday. Jefferies Group’s target price points to a potential downside of 15.19% from the stock’s previous close.

Durata Therapeutics (NASDAQ:DRTX) opened at 14.15 on Friday. Durata Therapeutics has a 1-year low of $7.81 and a 1-year high of $18.17. The stock has a 50-day moving average of $15.51 and a 200-day moving average of $14.38. The company’s market cap is $377.0 million. Durata Therapeutics also saw some unusual options trading activity on Friday. Traders bought 1,595 put options on the company. This is an increase of 656% compared to the typical daily volume of 211 put options.

Durata Therapeutics (NASDAQ:DRTX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.12. Analysts expect that Durata Therapeutics will post $-2.53 EPS for the current fiscal year.

A number of other firms have also recently commented on DRTX. Analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $24.00 to $28.00 in a research note on Tuesday, July 1st. Separately, analysts at Gabelli initiated coverage on shares of Durata Therapeutics in a research note on Friday, June 20th. They set a “hold” rating on the stock. Finally, analysts at JMP Securities reiterated an “outperform” rating on shares of Durata Therapeutics in a research note on Thursday, June 19th. They now have a $22.00 price target on the stock, up previously from $19.00. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.00.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.